OBJECTIVE The emergence of evolving variants of Coronavirus disease 2019(COVID-19)has fostered the need for change of newer and adaptive treatments for these infections.During the COVID-19 pandemic and persists,tradit...OBJECTIVE The emergence of evolving variants of Coronavirus disease 2019(COVID-19)has fostered the need for change of newer and adaptive treatments for these infections.During the COVID-19 pandemic and persists,traditional Chinese medicine(TCM)herbs exhibit significant bioactivity and therapeutic effect.This study is aimed to evaluate the efficacy of four TCM preparations on 28-day mortality risk of patients and changes of the laboratory indicators.METHODS The retrospective cohort study included patients with COVID-19 who were admitted to the Jiangsu Province Hospital of Chinese Medicine from December 15,2022 to January 15,2023,and those died within 48 hours of admission or cannot be tracked for outcomes were excluded.The primary outcome was survival status in 28 days(death or survival)starting from the day of admission.The second outcomes were laboratory indicators,including absolute lymphocyte count,lactate dehydrogenase,creatinine,and blood urea nitrogen.Binary logistic regressions were used to estimate the effect of TCM preparations on the primary and secondary outcomes in main analysis.Meanwhile,heterogeneity and robustness of results from main analysis were assessed by subgroup analyses and multiple sensitivity analyses.RESULTS 1816 eligible patients were included in analysis dataset,including 573 patients received standard care(control group)and 1243 patients received TCM preparations(hospital preparation group).The 28-day mortality rate of hospital preparation group was lower than that of control group(4.75%vs.14.83%),and the difference was statistically significant(χ^(2)=54.666,P<0.001).The risk of 28-day mortality was 0.535 times lower in the hospital preparation group as compared with the control group(OR=0.46,95%CI:0.305-0.708,P<0.001)showed by multivariable binary logistic regressions.Subgroup analyses showed that taking TCM preparations reduced the 28-day mortality risk.Sensitivity analyses demonstrated that the results of the main analysis for primary outcomes were robust.For secondary outcomes,the risk of abnormal absolute lymphocyte counts at discharge in the hospital preparation group decreased by 0.284 times(OR=0.703,95%CI:0.515-0.961,P=0.027).CONCLUSION Compared with standard of care,taking four hospital preparations including Kanggan Heji,Feining Heji,Qishen Gubiao Keli,and Qianghuo Qushi Qingwen Heji decreased risk of 28-day mortality among hospitalized COVID-19 patients.TCM therapy achieves adequate therapeutic effects in COVID-19.展开更多
Objective Studies of the association of hypertension with long-term exposure to particulate matter less than 2.5μm in diameter(PM2.5)have shown contradictory results and the magnitude of the association is still uncl...Objective Studies of the association of hypertension with long-term exposure to particulate matter less than 2.5μm in diameter(PM2.5)have shown contradictory results and the magnitude of the association is still unclear.Hence,we conducted a meta-analysis of cohort studies to assess the effect of long-term exposure to PM2.5 on incident hypertension.展开更多
Objective Telomere length, as an emerging marker of biological age,isrelatedwithhypertension.Ouraimistoinvestigatethe relationship between telomere trajectory and blood pressure change as well as the incident cardiova...Objective Telomere length, as an emerging marker of biological age,isrelatedwithhypertension.Ouraimistoinvestigatethe relationship between telomere trajectory and blood pressure change as well as the incident cardiovascular events in a longitudinal hypertensive cohort in China.展开更多
Background Arrhythmogenic right ventricular cardiomyopathy(ARVC)is an inherited primary cardiomyopathy characterized by myocardial degeneration with fibro-fatty replacement.Clinical and genetic features of ARVC were w...Background Arrhythmogenic right ventricular cardiomyopathy(ARVC)is an inherited primary cardiomyopathy characterized by myocardial degeneration with fibro-fatty replacement.Clinical and genetic features of ARVC were well identified in Caucasian cohorts,but seldom examined in Chinese cohort.Our aim is to examine the genetic factor,genotype-phenotype correlations,and inheritance patterns of ARVC in a Chinese cohort.展开更多
目的:鼻咽癌发病位置隐匿导致早期诊断率低,且具有明显的地域聚集性,是中国一个重要的公共卫生问题。本研究旨在通过2021年全球疾病负担(the Global Burden of Diseases,GBD)数据库分析中国鼻咽癌的疾病负担,为鼻咽癌的精准防控提供流...目的:鼻咽癌发病位置隐匿导致早期诊断率低,且具有明显的地域聚集性,是中国一个重要的公共卫生问题。本研究旨在通过2021年全球疾病负担(the Global Burden of Diseases,GBD)数据库分析中国鼻咽癌的疾病负担,为鼻咽癌的精准防控提供流行病学依据。方法:选取年龄标化发病率、病死率、伤残调整寿命年(disability adjusted life year,DALY)率作为疾病负担的评价指标,按照不同年龄、性别、社会人口学指数及其相关危险因素进行分层分析,同时应用差分自回归移动平均(autoregressive integrated moving average,ARIMA)模型和贝叶斯年龄-时期-队列分析模型(Bayesian age-period-cohort,BAPC)将年龄标化发病率预测至2050年。结果:2021年中国鼻咽癌年龄标化发病率、病死率、DALY率分别为3.4/10万、1.5/10万、48.7/10万,均高于同期全球水平。在所有年龄段,中国男性年龄标化发病率、病死率、DALY率均高于女性。中国鼻咽癌的疾病负担从1990至2021年随着社会人口学指数(socio-demographic index,SDI)的增高逐渐降低。中国归因于饮酒、吸烟、职业甲醛暴露的鼻咽癌疾病负担占比均高于全球水平,且在男性中尤为显著。模型预测中国及全球男性、女性、全人群的年龄标化发病率均提示从2022至2050年呈上升趋势。结论:既往30年中国鼻咽癌的疾病负担随着SDI的升高逐渐降低,但仍高于同期全球水平。同时,中国鼻咽癌的年龄标化发病率在未来30年呈上升趋势。中国仍需进一步增加医疗资源的投入以应对鼻咽癌的防控与诊疗,尤其针对高风险男性群体。展开更多
文摘OBJECTIVE The emergence of evolving variants of Coronavirus disease 2019(COVID-19)has fostered the need for change of newer and adaptive treatments for these infections.During the COVID-19 pandemic and persists,traditional Chinese medicine(TCM)herbs exhibit significant bioactivity and therapeutic effect.This study is aimed to evaluate the efficacy of four TCM preparations on 28-day mortality risk of patients and changes of the laboratory indicators.METHODS The retrospective cohort study included patients with COVID-19 who were admitted to the Jiangsu Province Hospital of Chinese Medicine from December 15,2022 to January 15,2023,and those died within 48 hours of admission or cannot be tracked for outcomes were excluded.The primary outcome was survival status in 28 days(death or survival)starting from the day of admission.The second outcomes were laboratory indicators,including absolute lymphocyte count,lactate dehydrogenase,creatinine,and blood urea nitrogen.Binary logistic regressions were used to estimate the effect of TCM preparations on the primary and secondary outcomes in main analysis.Meanwhile,heterogeneity and robustness of results from main analysis were assessed by subgroup analyses and multiple sensitivity analyses.RESULTS 1816 eligible patients were included in analysis dataset,including 573 patients received standard care(control group)and 1243 patients received TCM preparations(hospital preparation group).The 28-day mortality rate of hospital preparation group was lower than that of control group(4.75%vs.14.83%),and the difference was statistically significant(χ^(2)=54.666,P<0.001).The risk of 28-day mortality was 0.535 times lower in the hospital preparation group as compared with the control group(OR=0.46,95%CI:0.305-0.708,P<0.001)showed by multivariable binary logistic regressions.Subgroup analyses showed that taking TCM preparations reduced the 28-day mortality risk.Sensitivity analyses demonstrated that the results of the main analysis for primary outcomes were robust.For secondary outcomes,the risk of abnormal absolute lymphocyte counts at discharge in the hospital preparation group decreased by 0.284 times(OR=0.703,95%CI:0.515-0.961,P=0.027).CONCLUSION Compared with standard of care,taking four hospital preparations including Kanggan Heji,Feining Heji,Qishen Gubiao Keli,and Qianghuo Qushi Qingwen Heji decreased risk of 28-day mortality among hospitalized COVID-19 patients.TCM therapy achieves adequate therapeutic effects in COVID-19.
文摘Objective Studies of the association of hypertension with long-term exposure to particulate matter less than 2.5μm in diameter(PM2.5)have shown contradictory results and the magnitude of the association is still unclear.Hence,we conducted a meta-analysis of cohort studies to assess the effect of long-term exposure to PM2.5 on incident hypertension.
文摘Objective Telomere length, as an emerging marker of biological age,isrelatedwithhypertension.Ouraimistoinvestigatethe relationship between telomere trajectory and blood pressure change as well as the incident cardiovascular events in a longitudinal hypertensive cohort in China.
文摘Background Arrhythmogenic right ventricular cardiomyopathy(ARVC)is an inherited primary cardiomyopathy characterized by myocardial degeneration with fibro-fatty replacement.Clinical and genetic features of ARVC were well identified in Caucasian cohorts,but seldom examined in Chinese cohort.Our aim is to examine the genetic factor,genotype-phenotype correlations,and inheritance patterns of ARVC in a Chinese cohort.
文摘目的:鼻咽癌发病位置隐匿导致早期诊断率低,且具有明显的地域聚集性,是中国一个重要的公共卫生问题。本研究旨在通过2021年全球疾病负担(the Global Burden of Diseases,GBD)数据库分析中国鼻咽癌的疾病负担,为鼻咽癌的精准防控提供流行病学依据。方法:选取年龄标化发病率、病死率、伤残调整寿命年(disability adjusted life year,DALY)率作为疾病负担的评价指标,按照不同年龄、性别、社会人口学指数及其相关危险因素进行分层分析,同时应用差分自回归移动平均(autoregressive integrated moving average,ARIMA)模型和贝叶斯年龄-时期-队列分析模型(Bayesian age-period-cohort,BAPC)将年龄标化发病率预测至2050年。结果:2021年中国鼻咽癌年龄标化发病率、病死率、DALY率分别为3.4/10万、1.5/10万、48.7/10万,均高于同期全球水平。在所有年龄段,中国男性年龄标化发病率、病死率、DALY率均高于女性。中国鼻咽癌的疾病负担从1990至2021年随着社会人口学指数(socio-demographic index,SDI)的增高逐渐降低。中国归因于饮酒、吸烟、职业甲醛暴露的鼻咽癌疾病负担占比均高于全球水平,且在男性中尤为显著。模型预测中国及全球男性、女性、全人群的年龄标化发病率均提示从2022至2050年呈上升趋势。结论:既往30年中国鼻咽癌的疾病负担随着SDI的升高逐渐降低,但仍高于同期全球水平。同时,中国鼻咽癌的年龄标化发病率在未来30年呈上升趋势。中国仍需进一步增加医疗资源的投入以应对鼻咽癌的防控与诊疗,尤其针对高风险男性群体。
